Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Perhaps we're the lucky ones, not only for being investors here, but in doing so knowing about the Tollovid product and taking actions to protect ourselves and our families.
By the way, I saw earlier that Gerald had commented on the India trial on Twitter. It will be included in my daily Twitter update post later tonight.
I continue to believe the 3CL Sciences subsidiary will be acquired by one of the big pharma companies. Gerald has structured this joint venture between NLC Pharma and Todos Medical with that in mind, in my opinion. But he has to speak to plans for the subsidiary moving forward on its own in order to convey to interested parties we have a plan for competing with them if we keep the assets and subsidiary in house. Potential buyers will have to assess the value not based on TOMDF share price but multiples of potential worldwide revenue from what is likely going to be the most effective SARS-CoV-2 antiviral currently available on the planet.
Once the data is in and proves the worth of Tollovir, I anticipate multiple competing offers to acquire the assets. As Gerald stated on the CC, they have a price in mind and if this price is met, I expect the company will offload the subsidiary and related assets to the highest bidder. NLC Pharma will still benefit as will Todos shareholders, and the company will then be able to focus fully on their diagnostic assets Videssa and Lympro.
On any such buyout offer, I would likely sell one-third to one-half of my shares and continue to hold the rest for these assets to be brought to market.
Lots of options ahead. Exciting times for shareholders. Looking forward to the interim data release.
CEO on Twitter - 12/2/21
Article Link: https://www.medrxiv.org/content/10.1101/2021.12.01.21267147v1
After we uplist, I will definitely try to attend the next shareholders meeting. Hopefully the Covid threat will be greatly diminished by then with the success of the Tollovir/Tollovid products and great investment returns that would encourage investors to attend just to celebrate and meet the team who made this possible, as well as fellow shareholders who believed enough in this company to invest. GLTA
Sorry, previous posted price was in error. It was $84.15 with discount. Even better.
Regarding Amazon reviews, better to identify yourself as a Tollovid Daily user, not as a shareholder. Readers would care to know if you actually used the product, and as you stated, the shareholder bias might lessen the impact of your review. However, like you, I'm excited to be a shareholder in the company. Great things ahead for our investment.
I haven't used Tollovid Daily but instead purchased a bottle of the full strength Tollovid to keep in reserve. However, I have read all positive reviews on Amazon for the daily product. It seems there is an impact on overall health with this product, not just the 3CL protease inhibition.
I appreciate your product feedback here, and I just ordered a bottle of the Daily to try for myself. $86.15 with the TOLLO15 discount code. I will probably start renewing every month because this seems like an excellent protection against the SARS-CoV-2 virus.
I can offset part of this new monthly cost by moving to a lower cost cell phone plan. My well being is more important than more features on a phone plan.
I know some have commented on the cost. That's certainly a valid point. However, I once heard a question that put things in perspective for me. If your child or your spouse was diagnosed with a terminal disease and there was a cure but it cost $5,000 and could only be purchased for cash, and not cash you had already saved or generated by selling something, but cash you had to save to purchase the cure AFTER the diagnosis, how many could do it? Probably all of us, because this forces us to focus on what's truly important to us in how we spend our money. Same thought process here... even if I didn't think I could afford this, if it protected my loved ones, I could find a way to make it work. I could find a way to cut other expenses. Is that cell phone plan, multiple streaming services, appliance warranty plan, etc. worth the well being of my loved ones? It's a lot easier to cut out the unnecessary things when you think about it in those terms. Or I could delivery pizza for Dominoes 1 or 2 nights a week or on weekends and generate more than enough income to pay for Tollovid Daily.
And with not being restricted under those conditions, I could sell stuff on eBay or Craisglist and generate cash to fund Tollovir. Lots of options are available. I'm actually moving in that direction myself. GLTA
The company consulted about starting an India trial, and trials cost a lot of money. The hospitals don't do this work for free, and neither do those who establish the conditions and endpoints of the trial. A trial costs the company millions to conduct, and likely more to conduct with the rigor needed to prove to the regulators and review boards your product works.
Guess what also happened during this period... revenue from lab tests and reagent sales dropped dramatically. What happens when revenue drops? You either postpone plans until revenue flow is better able to support plans, or you issue more shares to pay for it.
Which one do you want? One can complain that GC failed to follow through on something that got postponed or cancelled due to lack of ability to pay for it, or complain about him issuing shares to pay for it.
This isn't meant to be an attack on you voicing your viewpoint, so I hope you don't take it that way. It's meant to get shareholders to consider the options the company faces every day for every plan to move forward. There's a lot going on that we as shareholders never see, so it's easy for us to criticize. A lot of things we didn't know about were discussed on the CC. Some of those plans may not become a reality based on any number of reasons. But those that do succeed open up new revenue streams and partnerships that should increase our exposure and elevate share price.
GC has a lot of negative baggage regarding what happened with Amarantus. One question on the CC was about how this uplist will differ from the one done with Amarantus, and I thought he nailed it in explaining the differences and how Todos won't have the same issues. I had some concerns about that as well, and after learning a few things about our uplist, I feel more confident than ever, and I am pleased they're pushing the uplist out until Q1 2022 because they want the share price much higher in order to minimize or eliminate need for a RS. This time GC seems more focused on how this impacts shareholders instead of rushing foolishly ahead to get uplisted at any cost.
GLTU
Share Structure Update - 12/3/21
No change in outstanding shares since last update on 11/19/21. I guess this squashes some recent posts about the price decline this week being caused by the company dumping shares. ZERO SHARES ISSUED.
https://www.otcmarkets.com/stock/TOMDF/security
That's okay. Let others unload their shares over their uncertainty. Picked up another 10K shares at the open. Adding more next week as funds become available. I'm very encouraged after yesterday's CC. Lots of confidence exhibited by the CEO and others speaking on behalf of Todos and we learned about some aspects of their plan we didn't previously know about. We know what we own, even if others are not yet aware of it. The excitement I'm feeling is similar to when I was a kid at Christmas waiting to open my presents. Overall a great CC. I've listened to it 3 times already.
Best wishes to all invested here.
I agree with your assessment 100%. It was one of the best investor calls I've ever heard. I even got to ask a question on the call, and was very pleased with the response I received.
By all means, everyone here should spend some time listening to this call, and let it sink in for a few days, and then listen to it again.
I'm more confident now as an investor than any time since I've been following the company and buying shares along the way. Every concern I had was addressed. I expect to continue buying shares, even though I reached my earlier target.
NEWS: Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation
• Dr. Jules Mitchel now leading preparation for data lock and statistical analysis
• Business update call Today at 4:30PM EST
New York, NY, and Tel Aviv, ISRAEL, Dec. 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its 3CL biology-focused joint venture partner NLC Pharma, today announced that all 31 patients enrolled to date in Tollovir® Phase 2 clinical trial in hospitalized COVID-19 patients have completed study participation and the data are now being entered into the database for analysis. Dr. Jules Mitchel, a strategic advisor retained by Todos to assist with the analysis, is now leading preparation for data lock and statistical analysis. The Company expects data analysis to be completed in December 2021.
The management team of Todos Medical, including Mr. Gerald E. Commissiong, President and Chief Executive Officer, will host a conference call today, December 2nd at 4:30 p.m. EST to discuss the Company’s business progress in 2021 and provide a strategic outlook for the future.
The call information is as follows:
· Date: December 2, 2021
· Time: 4:30 p.m. Eastern Standard Time
· Direct Dial-in number: (669) 900-6833
· Meeting ID: 94945983568
· Passcode: 167897
This call is being webcast and can be accessed at https://audience.mysequire.com/webinar-view?webinar_id=6b97aec0-7ccb-4754-9a33-5c26d34d9597.
The call will also be available for replay by accessing https://audience.mysequire.com/webinar-view?webinar_id=6b97aec0-7ccb-4754-9a33-5c26d34d9597.
For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.
About Dr. Dorit Arad
Dr. Dorit Arad is a D.C. in physical organic chemistry from the Technion who has more than 25 years of experience in the life science industry as an international researcher, executive and entrepreneur. Dr. Arad is a pioneer in the discovery and development of 3CL protease biology related products and product candidates. Dr. Dorit Arad is an interdisciplinary scientist with expertise in Computer assisted Drug Design, Biotechnology, mechanism-based drug design, Diagnostics, infectious disease and cancer.
About Tollovir®
Tollovir® is a 3CL protease inhibitor and anti-cytokine therapeutic candidate for the treatment of the nidovirus subcategory of coronaviruses that includes SARS-CoV-2, COVID-19, SARS-CoV-1, MERS and 229E. Tollovir is made from all natural ingredients that are qualified to ensure strong inhibition of the 3CL protease in vitro, as well as strong anti-cytokine activity. Tollovir is currently in a Phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID-19. Tollovir will be developed for the treatment of hospitalized COVID-19 (severe and critical), moderate COVID-19, long-haul COVID and potentially pediatric COVID-19. Todos has licensed rights for Tollovir to T-Cell Protect Hellas S.A. for the Greek market.
About TolloTest®
TolloTest® is a 3CL protease diagnostic fluorescence platform technology that has demonstrated clinical proof of concept in hospital setting and outpatient settings in correctly identifying patients infected with COVID-19, including within 1-3 days of first exposure. TolloTest diagnostic tools are being developed to address key deficiencies with current SARS-CoV-2 rapid antigen and PCR technologies. TolloTest can provide results in less than ten (10) minutes, and potentially in as little as two (2) minutes. Data generated from two studies conducted with TolloTest demonstrate that: (1) it can identify SARS-CoV-2 infected patients earlier than rapid antigen testing (potentially earlier than PCR testing), (2) it can identify patients who are likely no longer infectious, but still test positive by PCR and (3) it can identify patients that are still likely infectious, but who have been released from quarantine based on time from positive PCR test. TolloTest assay formats are being developed for (1) point-of-care/at-home market and (2) rapid mass screening in community settings (airports, schools, offices).
About Tollovid® & Tollovid Daily™
Tollovid and Tollovid Daily are dietary supplement products, made from natural ingredients, that help support and maintain healthy immune function, and are also 3CL protease inhibitor products based upon in vitro functional assays that show inhibition of 3CL protease activity. Tollovid's 3CL protease inhibition activity release criteria is at least twice as stringent as Tollovid Daily's 3CL protease inhibition release criteria. Tollovid has a 5-day dosing regimen, with 4 doses of 3 pills taken each day that provides maximum immune support. Tollovid Daily is a twice daily immune support product that is designed to provide ongoing daily immune support for the person on the go.
About T-Cell Protect Hellas S.A.
T-Cell Protect Hellas (www.tcellprotect.com), based in Athens, Greece, is a European nutraceutical manufacturer and supplier of immune support dietary supplement products that is led by a world-class management team. The company has a retail distribution network of over 11,000 stores throughout Greece. Mr. Filippopoulos, the founder of the company, has been in the natural supplement industry for over 35 years and has launched some of the most well-known products in Europe with his vast retail network relationships. T-Cell Protect is rolling out the Tollovid family of Products under the T-Cell brand throughout Europe.
About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa® breast cancer blood test.
Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Additionally, Todos has entered into a joint venture with NLC Pharma to pursue the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses.
For more information, please visit https://www.todosmedical.com/.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.
Todos Corporate and Investor Contact:
Richard Galterio
Todos Medical
732-642-7770
rich.g@todosmedical.com
https://investor.todosmedical.com/news-events/press-releases/detail/159/todos-medical-announces-all-31-patients-enrolled-to-date-in
For once we're in agreement. Mark the calendar.
I appreciate the feedback. Do you have a gut feeling we're on the brink of something great here? Not some random gut feeling, but one based on solid science and a very sophisticated approach to making a major impact in dealing with this terrible virus that was unleashed on the world. I believe very soon we're going to be extremely glad we discovered this little company called Todos Medical and how they're going to change the world.
Very exciting times ahead. GLTA
And the plan is to use the successful uplisting of Todos to Nasdaq to increase value of the 78M TOMDF shares owned by Amarantus to restart the company, pay off existing debt, and have sufficient capital resources to move existing assets such as MANF and ESS through clinical trials to market. Seems to me like a solid plan based on what appears to be unfolding with Todos and their Tollovir antiviral.
Best wishes to those who continue to hold AMBS shares. I really hope this plan works out. I'm not invested here, but having reached my target of Todos shares, I will be buying AMBS shares over the next few weeks and months in order to benefit from this rebirth, to be held long-term. GLTA
Yes, most OTC companies dilute because they are still small companies that haven't generated sufficient revenue or profits to survive or grow without issuing shares. That's the risk one takes in choosing to invest in OTC stocks. It's not a perfect scenario, but we understand it.
Those who think the company can just go down to the local bank for a traditional loan in lieu of raising capital by issuing more shares should stick to investing in companies listed on national stock exchanges. OTC is a lot higher risk because of this characteristic, but the rewards are also potentially greater.
Thanks again, Captain Obvious.
I agree with your conclusion. It's interesting the company chose to announce the 3CL Sciences spin-out BEFORE the interim trial data is released. I would have expected it to be announced either jointly with the data or immediately afterwards.
Gerald stated in a recent interview the company had been contacted by a number of companies, so this is likely to set the stage for a possible buy-out, or as the Emerging Markets article stated, to separate the Covid assets from the rest of the company in order to perform a realistic valuation so a valid buy-out offer wouldn't be a low-ball offer based on current market cap.
I've been wondering how the NLC Pharma folks would benefit from this partnership. Glad to see it has been worked out so they are able to reap the rewards of their amazing work.
What's the point of your post, telling us what we already know? We understand that we invested in a company based in Israel and that it's an OTC stock (with plans to uplist to Nasdaq). Big deal. All of that is already factored in the share price.
As far as "regularly updated on the OTC" part, I have posted updates of outstanding shares as reported to OTC using the same link you previously provided for about a year now. The weekly update is rarely late. I can only remember two or three times it was updated at greater than one-week intervals, so they DO update regularly on OTC.
This instance of being not even a week late in updating OTC is your evidence the company is dumping shares on the market and driving the price lower, when virtually EVERY company trading is being driven lower when the crazy selling on fears of the new strain of SARS-CoV-2?
3 strikes... yeah right. This is a small company with limited number of employees managing a number of critical steps for the company at this time. Being a few days past the usual weekly update to OTC is NOT a reason for concern for shareholders, I assure you.
CEO on Twitter - 11/28/21
Translation: Emmanuel (Top Part) - Gerald (Bottom Part)
Link to article: https://www.nature.com/articles/s41593-021-00926-1
I believe that is possible although I haven't experienced it personally. A friend once told me this was possible. The Nasdaq application process generally takes from 6-8 weeks to complete. If all requirements are met except share price, once approval is given the uplist can be coordinated with the RS. If I remember correctly, the RS of the company he was invested in (forget the name) occurred after market close one one day and the stock was trading on Nasdaq the next.
That isn't what happened with Amarantus. In the interim between RS and Nasdaq approval/uplist the share price got hammered by short-sellers and driven below the minimum price requirement. It appears they didn't have all the ducks in a row and ready to uplist. Hopefully Gerald has learned his lesson and won't make the same mistake this time. From what he's revealed over the last few months regarding the uplist, it sounds like everything will be coordinated with news, share price, and Nasdaq listing approval tied together to uplist very quickly.
Well, of course they're subjective, but so are the owners reviewing an application to become a tenant in a luxury apartment building. You don't want just any Joe, Forkey or Bolo moving in regardless of their financial status.
Nasdaq wants to ensure high quality companies with solid reputations are listed with them. Why wouldn't Todos Medical qualify, especially if they've just released solid data that could make their Tollovir product a name known around the world as the best option for battling the SARS-CoV-2 virus?
I personally believe the subjective part is a slam dunk if the data is good and we meet the other requirements. GLTA
$4 share price isn't needed for initial listing on Nasdaq Capital Market. A closing price of $2 would qualify if all other requirements are met.
Straight from the Nasdaq Initial Listing Guide
https://listingcenter.nasdaq.com/assets/initialguide.pdf
Page 11 describes Nasdaq Capital Market requirements. For the Market Value of Listed Securities Standard. I believe we meet all requirements except share price. Significant news in the coming weeks could catapult the stock closer to or even above the minimum price required, where a small RS may or may not be needed. There are additional requirements for all Nasdaq market categories regarding corporate structure and governance, but I believe we already meet those as well (or will by time of Nasdaq listing application).
Stockholders' Equity: $4 million
Market Value of Unrestricted Publicly Held Shares: $15 million
Operating History: N/A
Market Value of Listed Securities: $50 million
Unrestricted Publicly Held Shares: 1 million
Unrestricted Round Lot Shareholders: 300
Market Makers: 3
Bid Price: $4 OR Closing Price: $2
I expect the phase 2 trial interim data will be released before Friday, December 10... possibly this week, by Friday, December 3.
The only reason to convert at the end of lockup period is to sell shares in the secondary market. With positive data and rising share price, don't feel they'd be inclined to sell. Nasdaq uplist is why they invested. The current financiers are not like the last bunch. These firms intended to be with us long-term and help guide the company when needed.
Exciting weeks ahead.
While Pfizer's PAXLOVID antiviral is clearly attacking the right mechanism (3CL protease) in stopping the virus, it's the other part that the media is downplaying that is the concern. They combine their protease inhibitor with the HIV drug ritonavir to extend the life of the inhibitor because it is easily metabolized on the bloodstream and would require much higher doses to be effective. There are a large number of adverse drug interactions with ritonavir that will limit it's use because it will not only increase the lifespan and effectiveness of the protease inhibitor drug but all of these other drugs as well. Therein lies the danger.
I was once prescribed a cholesterol-lowering drug that had an adverse interaction with a blood pressure drug I was taking, whereby it would increase the effectiveness of the blood pressure drug by up to 10x, which would be the equivalent of taking 10 pills daily instead of 1. No thanks. Glad I caught it, as both the doctor and pharmacist missed it. Thank God for the Internet where one can research these things instead of blindly following doctors orders. But the part I did follow was to eat healthier and exercise which alleviated the need for the drug.
I believe if Tollovir data is as good as we expect, and the product is marketed well and emphasizing that the ingredients had already been given to 5,000 people with no reported side effects, it could become the gold standard of SARS-CoV-2 antivirals. Our investment here should do extremely well.
That's why I want to be invested in both. I've hit my target share count for Todos. Now it's time to start buying Amarantus because most investors haven't made the connection, unless they watched one of Gerald's recent videos where he spelled out his plans for Amarantus rebirth via the uplist where the 78M shares of TOMDF will fund Amarantus' clinical trials of their assets going forward. Some feel he has abandoned Amarantus, but I disagree. One company's success can benefit the other, but both can't be done simultaneously as both companies require capital in order to move forward.
While Todos share price is expected to move significantly higher once their Tollovir phase 2 interim data is released, Amarantus would be the longer play here, and price is certainly right for loading up several hundred thousand or million shares and sitting on it for a year to see how it plays out. I know some who never sold their AMBS shares and are anticipating this strategy as well.
GLTA
While I understand some news outlets are already reporting that Omicron variant is a mild variant, what I'm seeing on Twitter from doctors and researchers round the world is something quite different. Many of them are reporting it's too early to tell what the impact of this mutated strain will be. There's simply not enough data yet to make an informed conclusion.
Sort of like the networks projecting the winner in an election 2 hours after the polls close with only 25% of the votes counted. A lot can change as more data comes in. While this may indeed pan out to be good news, it's just as likely to be the other kind.
One thing is for certain... this scare has raised the awareness of everyone as to what's possible with this virus, and the need for effective antivirals that will stop it.
Tollovid and Tollovid Daily are still available for purchase at www.mytollovid.com and if you use the code TOLLO15 you get a 15% discount on the price. This code doesn't apply to subscriptions.
Better to buy from mytollovid site anyway since Amazon charges sales tax and mytollovid site doesn't, but also includes free shipping as well as use of the discount code.
Exciting weeks and months ahead for shareholders, that's for sure.
CEO on Twitter - 11/27/21
Link referenced: https://www.weforum.org/agenda/2021/07/how-scientists-detect-new-covid-19-variants/
Link referenced: https://web.archive.org/web/20210922151556/https://www.weforum.org/agenda/2021/07/how-scientists-detect-new-covid-19-variants/
Interesting article. Thanks for posting. Yes, it could be the quintessential "game changer".
However, Todos is far ahead of the research on this plant and will be releasing study data very soon, and if the trial data supports the 2020 observational study (which it likely does), then Tollovir will show very strong efficacy which could easily make Tollovir/Tollovid the "game changer" in the SARS-CoV-2 space. The active ingredients inhibiting the viral replication function have already been given to 5,000 people so the safety record is already known to be rock solid.
This excerpt from the article describes the roadblocks that remain to be overcome in the development of this plant as a potential game changer.
After demonstrating its efficacy in the lab, the next step is actually developing treatments from TG, which would of course take time – as you might expect from an agent developed from a poisonous plant, it's going to take a significant amount of further research to turn it into something safe for humans.
Testing it against cell cultures and getting promising results is by no means even a guarantee that this antiviral would eventually pass a clinical trial, but it's a hugely exciting first step for sure.
VIDEO: Dr. Dorit Arad, Founder & CTO - NLC Pharma - B.Sc., M.S., D.Sc, PhD
https://www.tcellprotect.com/wp-content/uploads/2021/11/1621324156032.mp4
This is worth watching. She discusses the research into coronaviruses and discovery of the compound that inhibits the 3CL protease function.
There's plenty of news... just not specifically about Todos. The Nu Covid-19 variant just discovered has the entire world in turmoil due to the large number of mutations found. The scientific community is freaking out over the possible impact to current vaccinations and standard of treatments in use to fight Covid-19.
Todos is in the right place at the right time. Great time to be a shareholder.
Todos seeing big moves over last few days. Bodes well for those still holding AMBS shares. Gerald's plan is for Amarantus to sell their Todos shares after Nasdaq uplist to raise the funds needed to move their assets forward, a re-awakening of Amarantus.
Why is this the standard applied to TOMDF, yet there is much speculation on another board which you activity participate based on opinion posts, tweets from the CEO, and press releases from the company, yet SEC filings and financials for that company are scarce to non-existent and I see no such concerns expressed about that company. Different standards must apply to companies depending on whether one has an investment there or not.
more important than posts or tweets, are TOMDF SEC Filings...!
these filing are what seperates the dust from typical novice investor speculation and whimsical hype
just sayin...!